Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] Group 1: Product Development - HRS-5346 is an oral small molecule inhibitor targeting lipoprotein(a) [Lp(a)], which is a significant independent risk factor for atherosclerotic cardiovascular diseases [1] - There are currently no similar products approved for market in both domestic and international markets [1] - The cumulative research and development investment for HRS-5346 has reached approximately 76.3 million yuan (unaudited) [1] Group 2: Market Context - Elevated Lp(a) levels are the most common single-gene lipid disease globally, with prevalence rates in Chinese adults exceeding 30 mg/dL and 50 mg/dL at 18.67% and 8.41%, respectively [1] - Targeting Lp(a) through lipid-lowering therapies represents a significant breakthrough direction in the prevention and treatment of cardiovascular diseases [1]

Core Viewpoint - The company’s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, indicating significant progress in its development [1] Group 1: Product Development - HRS-5346 is an oral small molecule inhibitor targeting elevated lipoprotein(a) [Lp(a)] levels, which is a common single-gene lipid disorder and a typical manifestation of lipoprotein dysregulation [1] - Currently, there are no similar products approved for market release domestically or internationally, highlighting the uniqueness of HRS-5346 [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5346 project has reached approximately 76.3 million yuan (unaudited) [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临 2026-014 江苏恒瑞医药股份有限公司 关于回购公司 A 股股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的相关规定，现将公司回购股份的进展情况公告如下： 2026 年 1 月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股 份 17.5 万股，已回购股份占公司总股本的比例为 0.003%，购买的最高价为人民币 57.48 元/股，最低价为人民币 57.20 元/股，已支付的总金额为人民币 1,003.86 万元（不含交易费用）。 截至 2026 年 1 月 27 日，公司本次股份回购方案累计通过上海证券交易所交 易系统以集中竞价交易方式回购股份 907.37 万股，已回购股份占公司总股本的比 例为 0.14%，购买的最高价为人民币 70.00 元/股，最低价为人民币 57.20 元/股， 已支付的总金额为人民币 60,525.48 万元 ...

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical, has had its HRS-5346 tablets included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, marking a significant milestone as there are currently no similar products approved for market domestically or internationally [1] Group 1: Product Development - HRS-5346 tablets are designed to treat elevated lipoprotein (a) levels, addressing a niche in the pharmaceutical market [1] - The total research and development investment for the HRS-5346 project has reached approximately 76.3 million yuan [1] Group 2: Market and Regulatory Environment - The drug development process is influenced by various factors including technology, approval processes, and policies, indicating a complex regulatory landscape [1] - There are uncertainties regarding the review policies and future competitive dynamics in the pharmaceutical market [1]

证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-013 江苏恒瑞医药股份有限公司 申请日期：2025年12月16日 拟定适应症（或功能主治）：用于治疗脂蛋白（a）水平的升高。 理由及依据：经审核，本申请符合《药品注册管理办法》和《国家药监局关 于发布＜突破性治疗药物审评工作程序（试行）＞等三个文件的公告》（2020年 第82号）有关要求，同意纳入突破性治疗药物程序。 关于药物纳入突破性治疗品种名单的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日,江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医药 有限公司的HRS-5346片被国家药品监督管理局药品审评中心（以下简称"药审中 心"）纳入突破性治疗品种名单。现将相关情况公告如下： 一、药物的基本情况 药物名称：HRS-5346片 受理号：CXHL2400233 药物类型：化学药品 注册分类：1类 二、药物的其他相关情况 脂蛋白(a)[Lp(a)]水平升高是全球最普遍的单基因脂质疾病，是脂蛋白紊乱 的典型表现之一。中国成年人的Lp(a)水平 ...

恒瑞医药（600276）(01276)发布公告，于2026年1月27日该公司斥资人民币1003.86万元回购17.5万股A 股，回购价格为每股人民币57.20-57.48元。 ...

MACD金叉信号形成，这些股涨势不错！ 恒瑞医药1月27日公告，公司于2025年8月20日召开第九 届董事会第十八次会议审议通过了《关于以集 中竞价交易方式回购公司A股股份 方案的议案》,同意公司使用自有资金,以集中竞价交易方式回购公司 股份用于实 施A股员工持股计划｡回购价格不超过90.85元/股（含）,回购资金总额不低于10亿元且不超 过20亿元｡回购期限为自董事会审议通过回购股份 方案之日起12个月以内｡截至2026年1月27日，公司累 计回购907.37万股，占公司总股本的0.14%，回购价格区间为57.2元/股至70元/股，累计使用资金6.05亿 元（不含交易费用）。 ...

Core Viewpoint - Heng Rui Medicine announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center. HRS-5346 is an oral small molecule inhibitor targeting elevated lipoprotein (a) levels, with no similar products approved for market domestically or internationally [1] Group 1 - HRS-5346 is designed to treat elevated lipoprotein (a) levels [1] - The inclusion in the breakthrough therapy list indicates potential expedited development and review processes [1] - There are currently no comparable products approved for sale in the market, highlighting a unique market opportunity [1]

智通财经APP讯，恒瑞医药(01276)发布公告，于2026年1月27日该公司斥资人民币1003.86万元回购17.5 万股A股，回购价格为每股人民币57.20-57.48元。 ...

格隆汇1月27日丨恒瑞医药(01276.HK)发布公告，2026年1月27日耗资人民币1003.9万元回购17.5万股A 股，回购价格每股57.2-57.48元。 ...